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ABSTRACT 
Background 
Ethnic minority service users with schizophrenia and schizoaffective disorders may 
experience inequalities in care. There have been no recent studies assessing access to 
evidence-based treatments for psychosis amongst the main ethnic minority groups in the UK. 
Methods 
Data from nationally representative surveys from England and Wales, of 10512 people with a 
clinical diagnosis of schizophrenia or schizoaffective disorders, were used for analyses.  
Multi-level multivariable logistic regression analyses were used to assess ethnic minority 
inequalities in access to pharmacological treatments, psychological interventions, shared 
decision making and care planning, taking into account a range of potential confounders.   
Results 
Compared with White service users, Black service users were more likely prescribed depot/ 
injectable antipsychotics (odds ratio:1.56 (95% confidence interval:1.33-1.84). Black service 
users with treatment-resistance were less likely to be prescribed clozapine (odds ratio: 0.56 
(95% confidence interval: 0.39-0.79)). All ethnic minority service users, except those of 
mixed ethnicity, were less likely to be offered cognitive behavioural therapy, compared to 
White service users. Black service users were less likely to have been offered family therapy 
and Asian service users were less likely to have received copies of care plans (odds ratio:0.50 
(95% confidence interval:0.33-0.76)), compared to White service users. There were no 
clinician-reported differences in shared decision making, across each of the ethnic minority 
groups. 
Conclusions 
Relative to White service users, ethnic minority service users with psychosis were generally 
less likely to be offered  a range of evidence-based treatments for psychosis, which included 
pharmacological and psychological interventions as well as involvement in care-planning. 
Key words 
Inequalities; race; ethnic minority; schizophrenia; schizoaffective disorders; treatments; 
prescribing; CBT; family therapy; care plans 
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INTRODUCTION 1 
There have been longstanding concerns around the care which ethnic minority groups living 2 
with severe mental illnesses receive [1-3]. In particular, it is well documented that ethnic 3 
minority groups, and in particular Black people with psychosis, are more likely to experience 4 
complex[1] and coercive pathways into care[1, 4].  Concerns around coercive practices have led 5 
some to consider the role of prescribing inequalities by ethnicity, as prescribing practices may 6 
reflect discriminatory practices. A recent systematic review of studies, mostly from the US, 7 
suggested that ethnic minority groups were more likely to be prescribed typical 8 
antipsychotics over atypical antipsychotics[5]. Evidence from the UK has not indicated 9 
differences in prescribing quality by ethnicity, however these studies have been based on in-10 
patient populations, with relatively small numbers and have only assessed differences 11 
between Black and White patients[6, 7]. It is possible that inequalities in treatments may be a 12 
concern for other ethnic minority groups as well.  13 
There is less evidence on access to psychological treatments for schizophrenia in Black and 14 
minority ethnic groups. People with schizophrenia should be offered cognitive behavioural 15 
therapy (CBT) or family therapy [8], how far this quality standard is met within ethnically 16 
diverse populations, from recent data, remains unclear. Previous research, from almost a 17 
decade ago, suggested that Black Caribbean people with psychosis were less likely to receive 18 
psychotherapy[9], and Asian and Black service users under the care of community mental 19 
health teams were also less likely to be referred for psychological treatments[3]. It is possible 20 
that there have been changes since the introduction of the recent guidelines for schizophrenia 21 
[8] but there have been no up-to-date studies which have assessed this. 22 
Alongside the receipt of treatments for schizophrenia, service users with schizophrenia 23 
should be at the heart of decision-making. To this end, the choice of antipsychotic medication 24 
should be determined through discussion between clinician and the service user[8, 10], 25 
information relating to potential side effects alongside benefits should be clear[8, 10] and 26 
written information or an equivalent should be given to service users with schizophrenia and 27 
schizoaffective disorders[8, 10].  There should be a care plan jointly agreed between the 28 
clinician and service user and, if appropriate, with the involvement of carers[8, 10]. It is not yet 29 
clear how far standards relating to these aspects of shared decision making fall short for 30 
ethnic minority groups with schizophrenia.  31 
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We conducted a secondary analysis of nationally representative data of people living with 32 
schizophrenia and schizoaffective disorders, to determine whether there were differences in 33 
treatments (antipsychotic prescribing, psychological therapies, shared decision making and 34 
receipt of care plans) across ethnic minority groups. 35 
  36 
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METHODS 37 
Setting and participants 38 
The National Audit of Schizophrenia was a cross-sectional survey of all mental health 39 
care Trusts and Health Boards within England and Wales, and aimed to collect 40 
information on randomly selected patients from healthcare providers on the quality of 41 
care provided. In the UK, mental health Trusts provide mental healthcare to 42 
geographically distinct catchment areas and provide both in-patient and out-patient 43 
services and may also occasionally provide tertiary level services at the national level. 44 
Despite being separate mental health providers, Trusts are still expected to provide 45 
equivalent standards of care nationally. There have been two waves of data collection for 46 
the surveys, first in 2011[11] and then in 2013[12].  On each occasion, Trusts were asked to 47 
provide data on a random sample of 100 service users over the age of 18 with a diagnosis 48 
of ICD-10 F20.0-F20.9 (schizophrenia) or F25.0-25.9 (schizoaffective disorder) under the 49 
care of community-based services (community mental health teams and specialist teams) 50 
within the previous twelve months, with the diagnosis made before the age of 60 years. 51 
Patients on in-patient caseloads were excluded. Selection of patients for both surveys was 52 
based on established random selection techniques, which included an online 53 
randomisation tool or randomly generated numbers by the study team, with mental health 54 
Trusts generating a sampling frame which comprised case lists from teams or selecting 55 
cases centrally using online random selection techniques. Once service users were 56 
identified using these methods local staff were contacted and asked to fill out the data 57 
collection questionnaire, and were able to consult clinical case notes as well as with the 58 
service users’ general practitioners, if required. Service providers submitted the 59 
completed questionnaires via a secure online system. All Trusts were asked to verify if 60 
data were accurate, prior to analysis. A priori sample size calculations determined the 61 
number of returns needed in order to have adequate power to provide sufficient precision 62 
of proportions to make meaningful comparisons between services.  All responses were 63 
anonymised and kept confidential. Full details of the methods for both surveys, as well as 64 
the extensive piloting phase, have been reported elsewhere[11, 12].  65 
Data collection procedures 66 
Prior to conducting the first survey, focus groups were conducted, alongside a 67 
development phase for outcome indicators. A pilot study comprising six Trusts, was 68 
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conducted and further helped to inform methods of data collection. The resultant 69 
questionnaire took less than 20 minutes to complete. The final tool included specific 70 
measures designed to assess quality of care (prescribing, access to psychological 71 
treatments and receipt of physical health care monitoring and interventions) according to 72 
standards set through the National Institute for Health and Care Excellence (NICE) for 73 
the management of people with schizophrenia[8]. The findings related to physical health 74 
have been published elsewhere[13].  75 
Measures 76 
The surveys were designed to assess if standards were being met in the quality of care 77 
received by people with schizophrenia and schizoaffective disorders, according to 78 
national quality standards[11, 12]. Service users and providers of mental health services 79 
formed an expert reference group and were consulted in the development of the 80 
questionnaires. Across the two waves of data collection, questionnaires and instruments 81 
which had been successfully piloted and used in the first wave were kept similar to those 82 
employed in wave two. Except for a question on whether clinicians had provided service 83 
users with a care plan (asked only in the second wave of the survey, as this was not a 84 
national standard when the first survey was conducted, virtually identical information on 85 
all other indicators were collected across the two waves. 86 
Trusts were asked to provide information on currently prescribed antipsychotic 87 
medication- and were asked to list all currently prescribed antipsychotic medications with 88 
dose. Where service users were not currently prescribed antipsychotic medication, Trusts 89 
were asked to report detail relating to most recently prescribed medications. Information 90 
relating to current/ recent antipsychotic prescribing (excluding pro re nata (PRN) 91 
medications), in particular relating to type, dose and method of administration was 92 
collected. Measures for maximum doses reached (as percentage of recommended 93 
maximum doses according to British National Formulary guidelines[14] ) .  Evidence of 94 
concurrent prescribing of more than one antipsychotic medication at the same time was 95 
also noted from the responses given to the question asking after currently prescribed 96 
antipsychotic medications. Using this information a variable was created to identify 97 
individuals prescribed more than one antipsychotic medication at the same time, 98 
excluding clozapine. The name provided for each of the antipsychotic medications was 99 
used to determine type of antipsychotics (First generation/ second generation/ clozapine). 100 
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In addition, method of administration (oral/ depot) was also noted. Clinicians were asked 101 
whether they thought the patient was in remission and if not, the level of disability 102 
evident. Where clinicians reported that a patient was not in remission or had only partial 103 
remission with significant symptoms and disability, they were asked if clozapine had 104 
been offered. Evidence of prior or current psychological intervention ever being offered 105 
was noted (family therapy and cognitive behavioural therapy).. Service providers were 106 
also asked to report whether there was documented evidence that service users had been 107 
involved in deciding which antipsychotic medication should be prescribed, whether there 108 
was documented evidence in the notes that the service user had been provided with 109 
written information on medication or an alternative, and whether the benefits and the side 110 
effects of the medication had been explained.  111 
Trusts were asked to extract data on ethnicity from clinical records and indicate whether 112 
the service user was: White, Asian or Asian British, Black or Black British, Chinese or 113 
other ethnic group, Mixed and ‘Not stated’. These categories were retained for the 114 
analysis.  115 
Information on other socio-demographic indicators, including gender, age and team 116 
responsible for care (assertive outreach team, community mental health team, crisis 117 
resolution team, early intervention and ‘other’ teams) and information on diagnoses 118 
according to the International Classification of Mental Disorders-10 (ICD-10)[15] was 119 
collected, as well as duration of illness. 120 
Statistical analysis 121 
Simple descriptive analyses were initially conducted on each of the two datasets using 122 
one-way analysis of variance and chi-squared tests as appropriate. Multi-level random 123 
effects logistic regression models were then used to assess the association of individual-124 
level covariates, nested within mental health Trusts, with each of the treatment outcomes. 125 
These models specifically modelled the variance between ‘clusters’ (in this case trusts) as 126 
well as within clusters. Each of the individual-level variables (age, sex, ethnicity, ICD-10 127 
diagnosis, duration of illness, team providing care, remission status) were modelled as 128 
fixed effects, with ethnicity treated as the main exposure and all other variables as a 129 
priori confounders. For each model the Likelihood Ratio Test (LRT) for ‘rho’ or the 130 
Intra-Cluster Correlation coefficient (ICC) assessed clustering within the dataset, against 131 
a null hypothesis of no clustering. A statistically significant p-value from the LRT 132 
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indicates evidence of within-Trust clustering. Using this approach, the crude association 133 
of ethnicity with each of the treatment outcomes was derived, followed by the association 134 
of ethnicity with each of the treatment outcomes adjusted for a priori confounders. For 135 
analyses relating to clozapine prescriptions, models were re-run with the sample restricted 136 
to individuals who were not in remission or had only partial remission with significant 137 
disability. Prior to combining waves of the NAS an interaction term survey year*ethnicity 138 
was fitted in models for all outcomes. As there was no evidence in support of a statistical 139 
interaction, analyses were combined across the two years. All analyses were conducted in 140 
STATA 13[16]. 141 
  142 
10 
 
RESULTS 143 
At Trust-level, for the first wave, 60/64 (94%) of mental health Trusts provided data and 144 
for the second wave, all 64/64 mental health Trusts in England & Wales submitted data. 145 
At an individual-level, response rates were 85% in the first wave and 88% in the second 146 
wave.  147 
Table 1 highlights demographic features of the sample. In general, ethnic minority service 148 
users within the sample were younger than White  service users, with a similar sex 149 
profile. Service users who were in the Chinese/ ‘Other’ or Mixed Ethnicity groups were 150 
more likely to be diagnosed as having a schizoaffective disorder, whilst duration of illness 151 
was longer in the White group. A higher proportion of Black/ Black British service users 152 
were under the care of an assertive outreach team. 153 
[Table 1 here] 154 
Table 2 displays proportions accessing treatments for psychosis by ethnicity. The 155 
majority of service users (96% in full sample) were prescribed an antipsychotic 156 
medication. White service users  and people of Mixed Ethnicity were more likely to 157 
exceed recommended BNF dose limits and a larger proportion of Black/ Black British 158 
service users were prescribed a depot. For psychological treatments Asian/ Asian British 159 
service users were more likely to be referred to family therapies, while service users of 160 
Chinese/ ‘Other’ ethnicity, were less likely to have documented evidence of their being 161 
given a copy of their care plan.  162 
[Table 2 here] 163 
Table 3 displays adjusted odds ratios for the association of ethnicity with each of the 164 
treatment indicators from multi-level multivariable logistic regression models. Of note, 165 
Likelihood Ratio Tests which assessed the null hypothesis of no within-Trust clustering 166 
versus the alternative hypothesis of some within Trust clustering (i.e. LRT for rho=0, also 167 
known as the intra-cluster correlation coefficient (ICC)), were p<0.001 for each of the 168 
treatment indicators (antipsychotic prescribing, referrals for psychological therapies, 169 
shared decision making and whether service users had a care plan) displayed in table 3. 170 
This suggests that high levels of variance remained between NHS mental health Trusts 171 
after adjusting for all individual-level covariates, which may indicate that certain NHS 172 
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Mental Health Trust-level characteristics might  account for variability in treatment 173 
provision, despite adjustment for each of the individual-level covariates in the models. 174 
[Table 3 here] 175 
In adjusted models, relative to White service users with schizophrenia and schizoaffective 176 
disorders each of the ethnic minority groups, except people who were of Mixed ethnicity, 177 
were less likely to exceed BNF maximum doses for antipsychotic prescribing, although 178 
service users of Mixed ethnicity were more likely to experience high-dose prescribing 179 
relative to White service users (Table 3). Black/ Black British service users were more 180 
likely to be prescribed depot antipsychotics, compared to White service users. When 181 
analysis of clozapine was restricted to the sample of people with treatment resistant 182 
schizophrenia, Black/ Black British service users were less likely to be prescribed 183 
clozapine relative to White service users, with a trend towards a similar direction in the 184 
Asian/ Asian British group. In adjusted regression models, there was no evidence of an 185 
association between ethnicity and antipsychotic polypharmacy.  There were no reported 186 
differences by ethnicity with respect to clinicians reporting that they had provided service 187 
users with written information on medications, had explained the benefits or side effects 188 
of the most recent antipsychotic medication, or had involved patients in decisions around 189 
the choice of antipsychotic (Table 3).  190 
With respect to psychological therapies, in adjusted models, each of the ethnic minority 191 
groups except for the Mixed ethnicity group were less likely to have been offered 192 
cognitive behavioural therapy, relative to the White  group. The Asian/ Asian British 193 
group were more likely to have been offered family therapy, whereas Black/ Black British 194 
service users were less likely to have been offered family therapy, compared to White 195 
service users. Asian/ Asian British service users were less likely to have been given a 196 
copy of their care plans, compared to White service users. 197 
  198 
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DISCUSSION  199 
The findings from this nationally representative survey of schizophrenia and 200 
schizoaffective disorders, suggest large variations in the provision and offer of high 201 
quality treatments to ethnic minority service users compared to White service users. 202 
Differences were observed across the provision of antipsychotic medications, 203 
psychological therapies and care plans. Our findings also indicated that variability in 204 
estimates remained at Trust-level even after adjusting for individual-level attributes. This 205 
may indicate a need to consider systemic/ institutional factors, and could also include an 206 
assessment of area-level deprivation or own ethnic density, alongside individual-level 207 
factors in accounting for observed ethnic differences, in future work. We did not have 208 
Trust-level information to inform our analyses, and as such, residual confounding by 209 
Trust-level factors may be a concern. Future waves of the surveys and subsequent 210 
analyses could include Trust-level information (such as ethnic diversity, Trust size, Trust-211 
level policies focusing on ethnic minority disparities) which may inform future work in 212 
this area. 213 
The data for this study was collected prior to the introduction of the updated (2014) UK 214 
NICE guidelines for the management of schizophrenia[8], and were based on the standards 215 
set out in the earlier guidelines (2009). It is possible that since the introduction of the 216 
updated guidance, disparities may have improved; future planned sweeps of the NAS will 217 
be well placed to monitor this.  218 
Strengths and limitations 219 
This analysis derives from randomly selected records of service users with schizophrenia 220 
and schizoaffective disorders from all mental health Trusts in England and Wales. Across 221 
Mental Health Trusts, response rates were good. Therefore the findings are highly 222 
generalizable to individuals with these diagnoses, within these countries. Combining two 223 
waves of survey meant that more than 10,000 service users provided data for the analysis. 224 
This would have improved statistical power to detect differences. It was possible to 225 
survey a variety of treatments for schizophrenia and schizoaffective disorders, and the 226 
analyses were not just restricted to prescribing. The findings provide some indication of 227 
quality of care received by ethnic minorities with schizophrenia and schizoaffective 228 
disorders under the care of community outpatient teams. 229 
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One of the limitations of the study is that data were extracted from clinical records. It is 230 
possible that in some instances these records did not provide a complete picture of the 231 
care that people received. For instance, some patients may have been offered a 232 
psychological therapy or a copy of a care plan without this being documented in their 233 
notes.  234 
Race/ Ethnicity is a complex multi-faceted construct, with the two terms frequently used 235 
interchangeably across the international literature[17, 18]. Typically ‘race’ has been taken to 236 
refer to differences based on biological attributes, ethnicity reflects  the way in which 237 
individuals place themselves with respect to shared identity, cultural/ religious affiliations 238 
and positions of marginality[17]. As such, ethnicity may be assessed through self-report, 239 
but even here may be subject to change over time, and is not a static construct. Arguably 240 
both ‘race’ and ethnicity are social constructs, subject to change, and potentially capturing 241 
systems of oppression[18]. In this study we have preferred to use the terminology 242 
‘ethnicity’ to reflect the complexities of categorisation[19]. A limitation of this study was 243 
that we do not know how each of the Trusts collected this information on service users. It 244 
is possible that for at least some of the service users within the survey, ethnicity was not 245 
self-ascribed and was instead recorded by administrators or clinicians using visual 246 
attributes. In addition we only had relatively crude indicators for ethnicity and it is likely 247 
that differences between groups were masked. The ‘White’ group would have potentially 248 
included individuals of Irish ethnicity as well as other White ethnic groups. It is a 249 
limitation that we were unable to explore this further, given concerns around known 250 
mental health inequalities affecting these groups[20, 21], as well as a well-established 251 
association between migration in general, and schizophrenia[22]. In addition, the other 252 
ethnic groups (‘Black’, ‘Asian’, ‘Chinese’, ‘Other’, ‘Mixed’) would have contained 253 
individuals with differing countries of birth, language, migration and settlement histories 254 
and we were unable to assess these potential indicators of acculturation and migration 255 
further.  256 
Although we adjusted for a number of important variables in models we did not have 257 
information on socioeconomic position. Information on other clinical factors was also 258 
unavailable, including presence of other co-morbid conditions. It is possible that some of 259 
the estimates were confounded by these factors. We were able to assess the role of 260 
clustering at the Trust-level in accounting for variance but did not have any Trust-level 261 
attributes which could be added to the analyses. The role which systemic factors may play 262 
14 
 
in accounting for the differences (such as Trust-level commitment to delivering race 263 
equality, the financial status of mental health Trusts and associated availability of 264 
treatments and interpreters) may play a role in patterning differences in outcomes and 265 
could be investigated in future work[23].  266 
  267 
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Implications 268 
Prescribing differences 269 
Previous research has indicated that Black people may be more likely to be subjected to 270 
Community Treatment Orders (CTOs) (supervised treatment orders with stipulated 271 
conditions), in whom depot/ injectable prescriptions are also more likely[24]. In addition, 272 
in another study, participants prescribed depot formulations experienced and reported the 273 
depot to be more coercive and less empowering than people prescribed oral 274 
medications[25]. These findings do raise a potential concern around differing experiences 275 
of coercion across ethnic minority groups, but should also be considered against the 276 
potential harm/ benefits of depot- for example in a recent systematic review and meta-277 
analysis, the authors highlighted that depot preparations were more likely to reduce the 278 
risk of relapse, compared to oral preparations[26]. It is also possible that preferences for 279 
injectable medications follow differing cultural expectations for allopathic treatments[27].  280 
It is possible that the frequency of depot prescriptions by ethnicity observed in the present 281 
study reflected these and other factors, although we were unable to assess this further. 282 
Future research, potentially utilising qualitative methods, could explore this. 283 
Observed differences in antipsychotic dosing may have reflected differing sensitivities 284 
(e.g. to extrapyramidal side effects) to antipsychotic medications as well as differences in 285 
response to relatively lower doses of antipsychotics by ethnicity, within the sample[28, 29], 286 
alongside possible prescriber concerns regarding pharmacokinetic interactions. 287 
Differences in dose of antipsychotics may have been mediated through a number of 288 
factors including but not limited to tobacco use, dietary factors, illness behaviours, patient 289 
expectation/ adherence, age, gender and weight[28-30], alongside enzyme mediated 290 
differences in metabolism[29]. We were only able to adjust for some of these factors in our 291 
models. Research within this area is still relatively scant[28], specifically with respect to 292 
the role of cultural factors in shaping expectation and response to treatments[27, 28]. More 293 
could be done to understand this better.  294 
Clozapine is recommended for treatment resistant schizophrenia, where two or more 295 
previous antipsychotic medications have failed to control symptoms[8]. Clozapine has also 296 
been associated with a reduction in mortality from natural causes[31] and is associated 297 
with a lower all-cause and suicide mortality risk, relative to other antipsychotic 298 
medications[32]. The benefits of clozapine on mortality risk are not just due to frequent 299 
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contacts with health services[31]. A previous study from the UK did not find an association 300 
between ethnicity and theoretical delay in initiating clozapine[33], although studies from 301 
the US have indicated that Black and Hispanic Americans with treatment resistant 302 
psychosis were less likely to be commenced on clozapine than White Americans[34]. The 303 
findings from our analyses suggest that, despite similar proportions of individuals by 304 
ethnicity experiencing significant disability or only partial remission from symptoms, the 305 
Black/ Black British group and to an extent the Asian/ Asian British group, were less 306 
likely to be prescribed clozapine. The larger sample size and national representativeness 307 
of our sample may account for the differences between this and previous UK studies[33, 308 
35]. Ethnic minority disparities in clozapine use may be due to clinician concerns around 309 
potential side effects, including agranulocytosis, weight gain and type 2 diabetes 310 
mellitus[34]. The reasons for differences in clozapine prescriptions by ethnicity for 311 
treatment-resistant psychosis will require further exploration in future work.  312 
Psychological treatments 313 
Healthcare providers fell short of recommended guidelines for the management of 314 
schizophrenia[8] in ethnic minority groups. Although there are concerns that the wholesale 315 
imposition/ application of psychological therapies insensitive to cultural context may be 316 
Eurocentric, culturally adapted therapies have a role to play in the treatment of psychosis 317 
across cultures. Psychological therapies may help to improve therapeutic alliance, 318 
adherence to medication, insight, and may help to provide knowledge about a condition 319 
and therefore potentially address stigma[36].  320 
Although previous work has indicated increased dropout rates from clinical trials of 321 
insight-focused cognitive behavioural therapy in psychosis in African Caribbean and 322 
Black African service users[37], the question within the present study assessed whether 323 
cognitive behavioural therapy or family therapies had ever been offered, potentially 324 
indicating a belief by service providers that some of the ethnic groups, except for the 325 
Mixed group, were less suitable for cognitive behavioural therapy than White service 326 
users with schizophrenia. Cognitive behavioural therapy when culturally adapted is 327 
beneficial for the treatment of psychosis across cultures[37]. Of those studies which have 328 
included ethnic minorities in trials of Cognitive Behavioural Therapy for psychosis, no 329 
differences in response have been found for treatment resistant schizophrenia by 330 
ethnicity[38],  or in satisfaction with therapy[39].  In a recent clinical trial assessing 331 
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culturally adapted cognitive behavioural therapy for psychosis in Black British, African 332 
Caribbean/ Black African and South Asian Muslim individuals, the investigators noted 333 
that cognitive behavioural therapy was beneficial for the reduction of positive symptoms 334 
and depressed mood[37].  335 
Whereas Asian/ Asian British people (and to an extent Chinese/ ‘Other’ groups) were 336 
more likely than White service users to have been offered family therapy, this was less 337 
the case for Black/ Black British individuals within the survey. Family therapy may  be 338 
more acceptable to people from collectivistic cultures[40] and easier to deliver if 339 
individuals are in close contact with their families. A randomised controlled trial for 340 
family therapy in Black, Hispanic and White Americans indicated that culturally adapted 341 
family interventions were beneficial for psychotic symptoms compared to a 342 
psychoeducational control[41]. It was not possible to assess reasons for the variability in 343 
referral practices to family therapy by ethnicity within the study, although the lower rates 344 
of referral for the Black/ Black British group will require further exploration. 345 
Care plans  346 
Care plans form the core of high quality care and should be developed jointly between the 347 
service user and clinician; with a copy of the care plan given to the service user [42].  The 348 
care plan should include a psychiatric and psychological formulation and also detail 349 
aspects of physical health[42]. An important aspect of the care plan is to help promote 350 
socially inclusive opportunities (such as employment).  Although, in general, high 351 
proportions across the sample (>91%) had a copy of their care plan, relative to White 352 
service users, Asian/ Asian British service users were less likely to have received a copy 353 
of their care plan. This finding is consistent with a previous national patient satisfaction 354 
survey conducted more than a decade ago in the UK which also indicated low levels of 355 
satisfaction among Asian service users, for example with respect to being well informed/ 356 
having information on mental health services[3]. The findings in the current study 357 
highlight a need to ensure that basic standards of care are accessible in an equitable 358 
manner across all ethnic minority groups.   359 
Trust-level variation 360 
Finally, it is possible that Trust-level factors play an important role in determining 361 
variations in the treatment of psychosis by ethnicity[23]. Although our analyses hinted at 362 
18 
 
this, we were unable to assess this further. Future research could explore potential 363 
systemic/ institutional factors alongside individual factors which may impact on access to 364 
high quality treatments for psychosis in ethnic minority groups.  365 
Conclusion 366 
In conclusion, the findings of this analysis of data from a nationally representative survey 367 
of service users with schizophrenia and schizoaffective disorders, indicate ethnic minority 368 
disparities in psychotropic medication use and access to psychological treatments and 369 
care plans, in England and Wales. Greater efforts need to be made to ensure that people 370 
with psychosis receive interventions and treatments in an equitable manner. Further 371 
rounds of the audit planned for the coming years will provide evidence of progress being 372 
made, to ensure this at both local and national levels.  373 
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Table 1: Demographic features by ethnicity 
 
 
Full Sample White  
Asian/  
Asian British 
Black/  
Black British 
Chinese/ 
Other 
     
Mixed 
 
 
 
N (%) N (%) N (%) N (%) N (%) N (%) Anova/ χ2 
Total 10504  8368 
 
861 
 
883 
 
183 
 
209 
  Mean age in years (SD)   46.7 (13.4) 42.0 (12.2) 43.0 (11.9) 45.4 (13.7) 38.7 (12.0) F=52.6; p<0.001 
Sex   
           Male 6834 65% 5463 65% 538 62% 570 65% 117 64% 146 70% χ2= 5.01; p=0.29 
Female 3670 35% 2905 35% 323 38% 313 35% 66 36% 63 30% 
 Diagnosis  
 
 
          F20 (schizophrenia) 8854 84% 7010 84% 743 86% 778 88% 147 80% 176 84% χ2 = 16.21; p=0.003 
F25 (schizoaffective disorder) 1650 16% 1358 16% 118 14% 105 12% 36 20% 33 16% 
 Duration of illness   
           1 - 2 years 466 4% 330 4% 51 6% 55 6% 14 8% 16 8% χ2= 123.69; p<0.001 
2 - 4 years 961 9% 695 8% 106 12% 107 12% 22 12% 31 15% 
 4 - 10 years 2607 25% 1982 24% 270 31% 252 29% 49 27% 54 26% 
 10+ years 6470 62% 5361 64% 434 50% 469 53% 98 54% 108 52% 
 Level of remission   
           Full/ partial 7711 73% 6168 74% 617 72% 633 72% 137 75% 156 75% χ2= 3.44 p=0.49 
Significant disability or 
no remission 2793 27% 2200 26% 244 28% 250 28% 46 25% 53 25% 
 Clinical team responsible for 
care 
 
 
 
          Community Mental Health 
Team 
7435 71% 
6062 72% 597 69% 532 60% 131 72% 113 54% χ2= 137.93; p<0.001 
Assertive Outreach Team 1294 12% 1004 12% 93 11% 143 16% 14 8% 40 19% 
 Early Intervention 520 5% 338 4% 66 8% 75 8% 14 8% 27 13% 
 Other  incl. Crisis Resolution 
Team 
1255 12% 
964 12% 105 12% 133 15% 24 13% 29 14% 
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Table 2: Receipt of treatments by ethnicity 
 
Full sample White  
Asian/  
Asian British 
Black / 
Black British 
Chinese/ 
Other Mixed 
  
 
N (%) N (%) N (%) N (%) N (%) N (%) χ2 ; p value
Totals 10504 
 
8368 
 
861 
 
883 
 
183 
 
209 
  Antipsychotic prescribing 
             In receipt of an antipsychotic 10111 96% 8068 96% 828 96% 839 95% 174 95% 202 97% χ2=5.16; p = 0.27
Prescribed SGA vs FGA† 4396 65% 3362 64% 428 70% 418 63% 97 73% 91 68% χ2=13.41; p=0.009 
Prescribed depot 3336 32% 2640 32% 257 30% 335 38% 46 25% 58 28% χ2=22.4; p<0.001 
Prescribed clozapine1 719 26% 589  27% 57 23% 46 18% 12 26% 15 28% χ2=9.18; p=0.06 
Prescribed >100% BNF 
recommended dose 1048 10% 869 10% 69 8% 65 7% 16 9% 29 14% χ2=15.82; p = 0.003 
Prescribed 2+ antipsychotics, 
exc. clozapine 1229 12% 1019 12% 91 11% 78 9% 16 9% 25 12% χ2=11.50; p = 0.02 
 
Shared decision making  
             Service user involved in 
deciding which antipsychotic 
prescribed 6070 59% 4861 59% 470 55% 514 59% 99 55% 126 62% χ2=6.17; p = 0.19 
Provided with written info on 
medication or alternative  4244 41% 3373 40% 349 41% 367 42% 71 39% 84 41% χ2=0.69; p = 0.95 
Benefits/ side effects of the 
antipsychotic explained 7421 71% 5885 71% 604 70% 650 74% 125 69% 157 76% χ2=6.94; p = 0.14 
 
Psychological treatments 
             CBT ever offered 3578 34% 2826 34% 276 32% 325 37% 57 31% 94 45% χ2=16.60; p = 0.002
Family therapy ever offered 1554 15% 1176 14% 187 22% 114 13% 36 20% 41 20% χ2=46.35;  p<0.001 
 
Care plan‡ 
             Service user has a current care 
plan 5263 95% 4208 96% 408 91% 435 96% 98 91% 114 98% χ2=24.34; p<0.001 
Key †Second Generation Antipsychotic (SGA) versus First Generation Antipsychotic (FGA), excluding people prescribed either clozapine, both FGA & SGA or no 
antipsychotics, totals: full sample n=6775; White n=5237; Asian/ Asian British n=612; Black/ Black British n=661; Chinese/ Other n=132; Mixed n=133;1clozapine 
prescribing restricted to n=2793 people not in remission (partial remission with substantial disability or not in remission at all) ‡Asked in second wave only 
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Table 3: Receipt of treatments by ethnicity* 
Key: *Reference group for all analyses are the White ethnicity group;**excludes people prescribed combination of drugs, no drugs or clozapine; 1Clozapine 
restricted to people not in remission (partial remission with substantial disability or not in remission at all); ‡ Second wave only; All models adjust for age, sex, managing 
team, duration of illness, diagnosis, remission and NAS survey year  
  
    Asian/ Asian British Black/ Black British Chinese/ Other Mixed LRT 
  N/ total OR 95% CI OR 95% CI OR 95% CI OR 95% CI p value 
Antipsychotic prescribing                     
Not in receipt of an antipsychotic 393/10504 1.01 0.69,1.47 1.26 0.89,1.77 1.24 0.62,2.49 0.78 0.36,1.70 0.66 
Prescribed SGA vs FGA** 4396/6769 0.91 0.75,1.10 1.17 0.97,1.41 0.72 0.48,1.07 1.06 0.72,1.56 0.13 
Prescribed depot 3336/10504 1.07 0.90,1.26 1.56 1.33,1.84 0.83 0.59,1.17 1.01 0.74,1.40 <0.001 
Prescribed clozapine1` 719/2793 0.76 0.55, 1.06 0.56 0.39, 0.79 0.96 0.48, 1.92 1.10 0.58, 2.08 0.01 
Prescribed >100% BNF recommended dose 1048/10504 0.82 0.63,1.08 0.77 0.58,1.02 0.88 0.52,1.50 1.58 1.05,2.38-- 0.04 
Prescribed 2+ antipsychotics, exc. clozapine 1229/10504 1.00 0.79,1.28 0.86 0.66,1.11 0.77 0.46,1.31 1.20 0.79,1.86 0.54 
                      
Shared decision making                      
Service user involved in deciding which 
antipsychotic prescribed 
6070/10334 
0.85 0.73, 0.99 1.07 0.92,1.26 0.93 0.68,1.27 1.08 0.80,1.45 0.17 
Provided with written info on medication or 
alternative  
4244/10455 
0.97 0.83,1.14 1.04 0.88,1.22 0.96 0.70,1.32 0.94 0.70,1.27 0.96 
Benefits/ side effects of the antipsychotic 
explained 
7421/10461 
0.93 0.79,1.10 1.15 0.96,1.37 0.97 0.70,1.35 1.20 0.86,1.68 0.31 
                      
Psychological treatments                     
CBT ever offered 3578/10495 0.73 0.61,0.86 0.74 0.63,0.88 0.69 0.49,0.97 1.10 0.82,1.48 <0.001 
Family therapy ever offered 1554/10493 1.53 1.26,1.86 0.76 0.60,0.95 1.39 0.93,2.06 1.01 0.70,1.47 <0.001 
                      
Care plan‡                     
Service user has a current care plan 5263/5520 0.50 0.33,0.76 1.29 0.74,2.26 0.53 0.26,1.10 2.38 0.56,10.12 0.002 
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